A review on Flurbiprofen: Therapeutic challenges in Emerging Active Metabolizing Biphenyl

Authors

  • Anju Khullar Department of Chemistry, General Shivdev Singh Diwan Gurbachan Singh Khalsa College, Patiala, Punjab 147001, India

DOI:

https://doi.org/10.48165/

Keywords:

Flurbiprofen (FLB), nonsteroidal anti inflammatory drug (NSAID), Nitroflurbiprofen, Anti-Alzheimer's disease, analgesic, analgesicarthritis, Antigingivitis, Antirheumatoid Antitumor, Antipyretic, Antiinflammatory and Radio protective properties

Abstract

Flurbiprofen is chemically 2-(3- fluoro-4- Biphenyl) propanoic acid. It is a nonsteroidal anti-inflammatory drug (NSAID) which has also  been found effective in the treatment of  rheumatoid arthritis and degenerative joint  diseases. R-Flurbiprofen has been utilized in the  treatment of neoplastic diseases such as breast  cancer, lung cancer, prostate cancer as well as  cystic fibrosis and Alzheimer's disease.  Flurbiprofen has shown an excellent therapeutic  action against many diseases and has been  reported to acquire anti-inflammatory, analgesic,  antipyretic, antimicrobial, antipyretics, antithrombotic, antinociceptive, anti-tumour and  radio protective activities. The derivatives of  flurbiprofen have been reported to contribute  significantly in controlling various diseases. In this context, the present report deals with the  summary of therapeutic uses of Flurbiprofen and  its various combinations that play an important  role in controlling painful and deadly diseases  along with reducing serious side effects caused  by the typical medical treatment. It is also used in  the treatment of rheumatoid arthritis and  osteoarthritis.  

Downloads

Download data is not yet available.

References

. G.D. Gupta, S.jain and N.K.jain, (1997). Pharmazu, 52: 709. [2]. Aamir MF, Ahmad M, Murtaza G, Khan SA. (2011). In Vitro/In Vivo Assessment of Flurbiprofen-Matrix type Transdermal Delivery System. Latin Am J Pharm.; 30(2): 318-324. [3]. Sharif A, Rabbani ME, Akhtar MF, Akhtar B, Saleem A, Farzana K, Usman A, Murtaza G. (2011). Design and evaluation of modified release bilayer tablets of Flurbiprofen. Adv Clin Exp Med., 20(3): 343–349.

. S. Uchita, T. Morishita, Y. Ikeda and T. Akashi, (1995). Jpn. J. Pharmacol., 69: 37. [5]. Khan SA, Ahmad M, Murtaza G, Aamir MN, Madni MA, Kousar R, Asghar MW. (2010). Formulation of two-drug controlled release non-biodegradable micro particles for potential treatment of muscles pain and spasm and their simultaneous spectrophotometer estimation. Acta Pol. Pharm. Drug Res., 67(3): 299-306.

. Shahzad, M. K, Ubaid, M, Raza, M, Murtaza G. (2013). The formulation of Flurbiprofen loaded microspheres using hydroxypropylmethylcellulose and ethyl cellulose. Adv. Clin. Exp. Med. 22(2): 177-183.

. Ahmad M, Ahmad R, Murtaza G. (2011). Comparative Bioavailability and Pharmacokinetics of Flurbiprofen 200 mg SR Pellets from India and France. Adv Clin Exp Med., 20(5): 599-604. [8]. M. El-Sadek, L.Abdel-Aziz and K. Abdel-Rahem, (1996). Zagazig J. Pharma. Sci., 5: 29. [9]. Candelario-Jalil E, Gonzalez-Falcon A, GarciaCabrera M, Alvarez D, Al-Dalain S, Martinez G, León OS, Springer JE. (2003). Assessment of the relative contribution of COX-1 and COX-2 isoforms to ischemia-induced oxidative damage and neurodegeneration following transient global cerebral ischemia. Neurochem, 86: 545-555.

. Welling PG, Dobrinska MR, (1987). Dosing Considerations and bioavailability assessment of controlled drug delivery system. In controlled drug delivery. Fundamental applications, Robinson J.R., Lee VHL.2nd Edition.Published by Marcell Dekker, Inc. New York, 29: 253-289.

. G. Cirino, C. Cicala, F. Mancuso, A.R. Baydoun and L.Wallace, (1995). Throm.Res.79: 73. [12]. http:// www.drugbank.ca/drugs/DB00712(17 June 2014).

. S. Panday, U.V.Singh and N. Udupa, (1994). East. Pharm, 37: 181.

. Karande P, Mitragotri S, (2009). Enhancement of transdermal drug delivery via synergistic action of chemicals. Biochimica etal Biophysica Acta, 1788: 2362–2373.

. H.J.Gill, W.Y.Lee and S.C. Chi, (1995). Chem.Abtrs, 123: 93017g.

. Roger Walker and Cate Whittlsea. (2008). Clinical pharmacy and Therapeutics. Elsevier Health Sci, 4th Ed.

. Harsh Mohan. (2003). Textbook of Pathology. Jaypee Brothers, Medical Publishers Ltd., 4th Ed., New Delhi.

. http://www.arthritistreatmendrelief.comnta. (Accessed on feb.2013). [19]. K. Nishio and A. Akimoto, (1997). Chem. Abtrs, 126: 108956a.

. H. J. Gill, J.W. Lee and S.C. Chi, (1995). Chem. Abtrs., 122: 230338 h

. Streubel, A., Siepmann, J., Dashevsky, A. and Bodmeier, R. (2000). pH-independent release of a weakly basic drug from water-insoluble and water-soluble matrix tablets. Journal of Controlled Release.,67: 101-110.

. Khan, G.M. (2001). Controlled release oral dosage forms: Some recent advances in matrix type drug delivery systems, The Science. 1; 350-354.

. K.Yamao, M. Hiramatsu, K. Hasegawa and T. Asai, (1995). Chem.Abtrs, 122: 238873n. [24]. Y. Yamao, Sato, T. Asai and T. Morita, (1996). Chem. Abtrs, 124: 97774 v. [25]. Lin SY, Kawashima Y. (2001). Current status and approaches to developing press-coated chronodelivery drug systems, J Control Release, 157: 331-53.

. D.S. Jones, C.R. Irwin, A.D. Woolfson, J. Djokic and V. Adams, (1999). J. Pharma. Sci. 88: 592. [27]. U. Bragger, T. Muble, I. Fourmosis, N.P. Lang and A. Mombelli, (1997). J.Periodontal Res., 32: 575.

. Peskar, B.M., Kluge, S., Peskar, B.A., Soglowek, S.M. and Brune, K. (1991). Effects of Pure Enantiomers of Flurbiprofen in Comparison to Racemic Flurbiprofen on Eicosanoid Release from Various Rat Organs ex Vivo.Prostaglandins, 42: 515-531.

. Carabaza, A., Cabré, F., Rotllan, E., Gómez, M., Gutierrez, M., Garcia, M.L. and Mauleón, D. (1996).

Stereoselective Inhibition of Inducible Cyclooxygenase by Chiral Nonsteroidal Antinflammatory Drugs. The Journal of Clinical Pharmacology, 36: 505-512.

. B.S. Rao and K.V. R. Murthi, (1996). Indian drugs, 33: 397.

. Sugimoto, M., Toda, Y., Hori, M., Mitanni, A., Ichihara, T., Sekine, S., Hirose, T., Endo, H., Futaki, N., Kaku, S., Otsuka, N. and Matsumoto, H. (2016). Analgesic Effect of the Newly Developed S (+)-Flurbiprofen Plaster (SFPP) on Inflammatory Pain in a Rat Adjuvant Induced Arthritis Model. Drug Development Research, 77, 20-28.

. R.F. Zernickle, G.R. Wohl, R.A. Greenwald, S.A. Maok, W. Leng and L.M. Golub, (1997). J.Rhematol, 24: 1324.

. K. Kawada, J. Tatsumi and N. Kurihara, (1997). Chem. Abtrs, 127, 314538q. [34]. Yataba, I., Otsuka, N., Matsushita, I., Kamezawa, M., Yamada, I., Sasaki, S., Uebaba, K., Matsumoto, H. and Hoshino, Y. (2016). Plasma Pharmacokinetics and Synovial Concentrations of S-Flurbiprofen Plaster in Humans. European Journal of Clinical Pharmacology, 72, 53-59.

. W. J. Wechter and J.D. McCracken, (1998). Chem. Abtrs, 128: 235144a. [36]. Kean WF, Antal EJ, Grace EM, Cauvier H, Rischke J, et al. (1992). The Pharmacokinetics of flurbiprofen in younger and elderly patients with rheumatoid arthritis. J Clin Pharmacol 32: 41-48.

. J.D. McCracken, W.J. Wechter, Y. Liu, R.L. Chase, D. Kantoci, E.D. Muurray (jr.) D.D. Quiggle and Y. Mineyama, (1996). J. Clin. P harmacol., 36: 540.

. Rosca ID, Vergnaud JM. (2010). Survey, calculation of the characteristics of oral diffusion controlled release dosage forms related to the drug, Eur. J Drug Met Pharmacokinet, 35: 29- 39.

. W.J. Wechter, D. Kantoci, E.D. Murray (jr)D.D. Quiggle, D.D. Leipold, K.M. Gibson and J.D. McCracken, (1997). Cancer Res., 57, 4316.

. L. Juchelkova, M. Hofer, M. Pospisil and I. Pipalova, (1998). Physiol. Res. (Prague), 47: 73. [41]. L. Juchelkova, M. Hofer, M. Pospisil and I. Pipalova, (1996). Folia-Biol (Prague), 42: 267 [42]. D.A. Gamache, S.T. Miller and J.M. Yanni, (1999).Chem. Abtrs, 131: 39763z. [43]. Fu XC, Wang GP, Liang WQ, Chow MS (2003). Prediction of drug release from HPMC

matrices; effect of physicochemical properties of drug and polymer concentration Control Release, 95: 209-216.

. V. Neugebauer, G. Geisslnger, P. Ruemenapp, F. Weiretter, I. Szelenyi, K. Brune and H.G. Schaible, J. (1995). Pharma.Exp.Ther., 275: 618.

. Vemula SK and Veera reddy PR. (2011). Fast disintegrating tablets of flurbiprofen: formulation and characterization, Latin. Am. J. Pharm., 3: 1135-1141.

. G.Geisslnger and H.G. Schaible (1996). J. Clin. Pharmacol., 36: 513.

. S. Mariotto, M. Menegazzi, A. Carcereri de Prati, L. Cuzzolin, A. Adami, H. Suzuki and G. Benoni, (1995). Br. J. Pharmacol, 116, 171.

. A. Fukahara, T. Imai, K. Inoue and M. Ptagiri, (1995). Biol. Pharma Bull., 18: 140. [49]. Vemula SK, Veera reddy PR and Devadasu VR. (2014). Pharmacokinetics of colon-specific pH and time dependent flurbiprofen tablets, Eur. J. Drug. Met. Pharmacokinet.doi: 10.1007/s13318-014-0210-0

. Veera reddy PR and Vemula SK. (2012). Formulation, evaluation and pharmacokinetics of colon targeted pulsatile system of flurbiprofen, J. Drug. Targ., 20(8): 703-714.

. Vemula SK and Veera reddy PR. (2012). Colon specific controlled release matrix tablets of flurbiprofen: formulation and characterization, Asian. J. Pharm. Clin. Res, 5: 92-96. [52]. J.L. Wallace, G. Cirino, G.W. McKnight and S.N. Elliott, (1995). Eur. J. Pharmacol. 280: 63. [53]. Vemula SK and Veera reddy PR. (2013). Formulation, evaluation and pharmacokinetics of ketorolac tromethamine time-dependent colon targeted drug delivery system, Exp. Opin. Drug, Del., 10: 3345.

. Vemula SK, Veera reddy PR and Devadasu VR. (2014). Pharmacokinetics of ketorolac tromethamine compression-coated tablets for colon delivery, Drug. Del. Trans. Res. 4; 310- 319.

. Cho H, Wolf KJ, Wolf EJ. (2009). Management of ocular inflammation and pain following cataract surgery: focus on bromfenac ophthalmic solution. Clin Ophthalmol (Auckland, NZ). 3: 199.

. E. Flescher and C.A. Synder, (1995). Arch. Toxicol., 69: 684.

. Sweetman CS. (2007). Martindale: The Complete Drug, Reference. Pharmaceutical Press, London.35th edition, 52-53.

. Renner B, Mueller CA, Shephard A. (2012). Environmental and non-infectious factors in the aetiology of pharyngitis (sore throat).Inflamm Res., 61: 1041–1052.

. Sefia E, Mann A, Lambkin R, et al. Flurbiprofen lozenges rapidly reduce levels of the inflammatory mediator prostaglandin E in human respiratory cells in vitro. Abstract presented at the Annual Scientific Meeting of the British Pain Society, 24–27 April 2007, Glasgow (Scotland24–27 April 2007).

. A.S. Mulato, E.S. Ho and T.Cihlar, (2000). J. Pharma.Exp.Ther., 295: 10. [61]. Russo M, Bloch M, de Looze F, et al. (2013). Flurbiprofen microgranules for relief of sore throat: a randomised, double-blind trial. Br J. Gen. Pract., 63e: 149–155.

. A. Schachtel B, Aspley S, Shephard A, et al. (2014). Onset of action of a lozenge containing flurbiprofen 8.75mg: a randomized, double-blind, placebo-controlled trial with a new method for measuring onset of analgesic activity. J. Pain., 155: 422–428.

. B. Schachtel B, Aspley S, Shephard A, et al. (2014). Utility of the sore throat pain model in a multiple-dose assessment of the acute analgesic flurbiprofen: a randomized controlled study. Trials. 15: 263.

. N.E. Cameron, M.A.C otter and T.C. Hohman, (1996). Diabetologia, 39: 172. [65]. Limb M, Connor A, Pickford M, et al. (2009). Scintigraphy can be used to compare delivery of sore throat formulations. Int. J Clin Pract., 63: 606–612.

. Schachtel BP, Fillingim JM, Beiter DJ, et al. (1984). Rating scales for analgesics in sore throat. Clin Pharmacol Ther., 36: 151–156.

. SIGN (Scottish Intercollegiate Guidelines Network).Management of sore throat and indications for tonsillectomy. 2010. Available at: http://www.sign.ac.uk/pdf/ sign117.pdf [accessed May 2015].

. Spinks A, Glasziou PP, Del Mar CB. (2013). Antibiotics for sore throat. Cochrane Database Syst Rev., 11: CD000023.

. R.C. Becker and F. Spencer, (1997). J. Thromb., 4: 197.

. Myles PS, Williams DL, Hendrata M, Anderson H, Weeks AM. (2000). Patient satisfaction after anaesthesia and surgery: results of a prospective survey of 10,811 patients. Br J. Anaesth., 84 (1): 6–10.

. Ye H, Chen R, Lian X, et al. Risk factors associated with postoperative pain and discomfort in oculoplastic surgery with general anesthesia: a prospective study. (2018). J Pain Res. 11: 407– 415.

. Lesin M, Sundov ZD, Jukic M, Puljak L. Postoperative pain in complex ophthalmic surgical procedures: comparing practice with guidelines. (2014). Pain Med., 15(6): 1036–1042. [73]. Cho H, Wolf KJ, Wolf EJ. Management of ocular inflammation and pain following cataract surgery: focus on bromfenac ophthalmic solution. (2009). Clin Ophthalmol (Auckland, NZ). 3: 199- 204.

. Sweetman CS. (2007). Martindale: The Complete Drug Reference.Pharmaceutical Press, London, 35: 52-53.

. Wittpenn JR, Silverstein S, Heier J, Kenyon KR, Hunkeler JD, Earl M,etal.A randomized, masked comparison of topical ketorolac 0.4% plus steroid vs. steroid alone in low-risk cataract surgery patients. (2008). American journal of ophthalmology, 146(4): 554-60.

. Silverstein SM, Cable MG, Sadri E, Peace JH, Fong R, Chandler SP, Gow JA, Klier SM, McNamara TR, (2011). Bromfenac Ophthalmic Solution Once Daily (Bromday) Study Group. Once-daily-dosing of Bromfenacophthalmic solution. 0.09% for postoperative-ocular inflammation and pain.Curr Med Res opin, 27(9): 1693-703.

. Jung JW, Chung BH, Kim EK, Seo KY, Kim TI. (2015). The effects of two non-steroidal anti inflammatory drugs, bromfenac 0.1% and ketorolac 0.45%, on cataract surgery. Yonsei Med J., 56 (6): 1671-77.

. Wang K, Luo J, Zheng L, Luo T. (2017). Preoperative flurbiprofen axetil administration for acute postoperative pain: a meta-analysis of randomized controlled trials. J. Anesth., 31(6), 852–860.

. Yeh YC, Lin TF, Lin FS, Wang YP, Lin CJ, Sun WZ. (2008). Combination of opioid agonist and agonist–antagonist: patient-controlled analgesia requirement and adverse events among different-ratio morphine and nalbuphine admixtures for postoperative pain. Br. J. Anaesth, 101(4): 542–548.

. Schnabel A, Reichl SU, Zahn PK, Pogatzki-Zahn E. (2014). Nalbuphine for postoperative pain treatment in children. Cochrane Database Syst Rev., 9(4): CD009583.

. Chou R, Gordon DB, de Leon-Casasola OA, et al. (2016). Management of postoperative pain: a clinical practice guideline from the American Pain Society, the American Society of Regional Anesthesia and Pain Medicine, and the American Society of Anesthesiologists’ Committee on Regional Anesthesia, Executive Committee, and Administrative Council. J Pain, 17 (2): 131–157.

. Weggen S, Estrilcscen JL, Das P, Sagi SA, Wang R, Peitrzik CU et al. (2001). A subset of NSAIDs lower amyloidogenic Abeta42, independentely of cyclooxygenase activity. Natures, 414: 212-16.

. Tsunematsu H, Yoshida S,Horic K, Yamarnoto M. (1995). Synthesis and the Stereoselective enzymatic hydrolysis of flurbiprofen-basic amino acid ethyl esters J Drug Target, 2: 517-25. [84]. Gairola N, Nagpal D, Dhaneshwar SS, Dhaneshwar SR, Chaturvedi SC (2005). Synthesis hydrolysis Kinetics and pharmocologynamic profile of novel prodrugs of flurbiprofen. Indian J Pharma .Sci., 67 (3): 363-73.

. Shrivastava SK, Jain DK, Shrivastava PK, Trivedi P, (2009). Flurbiprofen and suprofen dextran conjugates: synthesis, characterisation and biological evaluation. Trop. J .Pharma., Res, 8(3): 221-29.

. Philip AK, Dubey RK, Pathak K, (2008). Optimising Delivery of flurbiprofen to the colon using a targeted prodrug approach. J. Pharma., Pharmacol, 60: 607-13.

. Ibrahim MM, Sammour OA,Hammad MA, Megrab NA, (2008). In vitro evaluation of pronisomers as a drug carrier for flurbiprofen.AAPS, Pharma Sci Tech., 9(3): 782-90. [88]. Shen J, Gan L, Zhu C, Dong Y, Jiang M et al. (2011). Novel NSAIDS ophthalmic formulation: flurbiprofen axctil emulsion with law irritancy and improved anti inflammation effects, Int. J. Pharma, 412: 115-22.

. Bondi ML,Craparo EF, Picone P, Giammona G,Di Gesu R,Di Carlo M. (2013). Lipid nanocarriers containing ester prodrugs of flurbiprofen preparation, physical chemical characterisation and biological studies. J. Biomedical Nanotechnology, 9: 238-46.

. Dollery C. (1991). Therapeutic drugs. New York, NY: Churchill Livingstone. [91]. Andersen LJ, Poulsen T, Krogh B and Nielsen T (2007). Postoperative analgesia in total hip arthroplasty: A randomized double-blinded, placebo-controlled study on peroperative and postoperative ropivacaine, ketorolac, and adrenaline wound infiltration. Acta Orthop. 78: 187–192.

. Chen CX, Kwekkeboom KL and Ward SE. (2015). Self-report pain and symptom measures for primary dysmenorrhoea: a critical review. Eur. J. Pain, 19: 377–391.

. De Sanctis V, Soliman A, Bernasconi S, Bianchin L, Bona G, Bozzola M, Buzi F, De Sanctis C, Tonini G, Rigon F and Perissinotto E. (2015). Primary dysmenorrhea in adolescents: prevalence, impact and recent knowledge.Pediatr Endocrinol Rev., 13:512–520.

. Marjoribanks J, Ayeleke RO, Farquhar C and Proctor M. (2010). Nonsteroidal antiinflammatory drugs for dysmenorrhoea. Cochrane Database Syst Rev., 20(1): CD001751.doi: 10.1002/14651858.CD001751.pub2.

. Ju H, Jones M and Mishra G.The prevalence and risk factors of dysmenorrhea. Epidemiol Rev., 36,104–113(2014).

. Pollard, D.J.; Woodley, J.M. (2007). Trends Biotechnology, 25: 66–73.

. Tao, J.; Xu, J.H. (2009). Curr. Opin. Chem. Biol., 13: 43–50.

. Hayball, P.J. (1996). Drugs. 52: 47–58.

. Shen, T.Y. Angew., (1972). Chem. Int. Edit., 11: 460–472.

. Spizzo, P.; Basso, A.; Ebert, C.; Gardossi, L.; Ferrario, V.; Romano, D.; Molinari, F. (2007). Tetrahedron. 63: 11005– 11010.

Tamborini, L.; Romano, D.; Pinto, A.; Bertolani, A.; Molinari, F.; Conti, P. J. Mol. (2012). Catal. B- Enzym., 84: 78–82.

. Ghanem, A. (2010). Chirality, 22: 597–603.

. Shin, G.S.; Lee, K.W.; Kim, T.K.; Shin, H.D.; Lee, Y.H. J. Mol. (2005). Catal. B-Enzym., 33, 93– 98.

. Plechkova, N.V.; Seddon, K.R. (2008). Chem. Soc. Rev., 37, 123–150.

. Shimomura, K.; Harami, H.; Matsubara Y.; Nokami, T.; Katada, N.; Itoh, T. (2015). Catal. Today, 255, 41–48.

. Jia, R., Hu, Y.; Huang, H. (2014). Process Biochem, 49: 668– 672.

. Singh, M.; Singh, R.S.; Banerjee, U.C. (2010). Process Biochem, 45: 25–29, [108]. Su, F.; Peng, C.; Li, G.L.; Xu, L.; Yan, Y. (2016). J. Renew.Energy., 90: 329–335. [109]. Tian, R.; Yang, C.H.; Wei, X.F.; Xun, E.N.; Wang, R.; Cao, S.G.; Wang, Z.; Wang, L. (2011). Biotechnology Bioproc.Eng, 16: 337– 342.

. Pan, S.; Liu, X.; Xie, Y.D.; Yi, Y.Y.; Li, C.; Yan, Y.J.; Liu, Y. (2010). Bioresour.Technol., 101; 9822–9824.

. Wang, J.; Wang, S.S.; Li, Z.J.; Gu, S.S.; Wu, X.Y.; Wu, F. J. Mol. (2015). Catal.B-Enzyme, 111: 21–28.

. Liu, Y.; Guo, C.; Liu, C.Z. Catal. (2014). Lett., 144: 1552–1556.

. McCormick Z, Chang-Chien G, Marshall B, Huang M and Harden RN (2014). Phantom limb pain: A systematic neuroanatomicalbased review of pharmacologic treatment. Pain Med 15: 292-305.

. Kushwaha N, Sahu S and Tyagi RK (2015). Flurbiprofen axetil loaded coaxial electrospun poly (vinylpyrrolidone) nanopoly (lactic- co-glycolic acid) core-shell composite nanofibers: Preparation, characterization, and anti-adhesion activity. J Appl Polym Sci, 132: 899-907.

. Lin X, Zhang R, Xing J, Gao X, Chang P and Li W (2014). Flurbiprofen axetil reduces postoperative sufentanil consumption and enhances postoperative analgesic affects in patients with colorectal cancer surgery.Int J Clin Exp Med, 7, 4887-4896.

. Wen Y, Wang M, Yang J, Wang Y, Sun H, Zhao J, Liu W, Zhou Z, Deng H, Castillo-Pedraza C, et al (2015). A comparison of fentanyl and flurbiprofen axetil on serum VEGF-C, TNF-α, and IL-1β concentrations in women undergoing surgery for breast cancer. Pain Pract, 15: 530-537.

Downloads

Published

2020-12-15

Issue

Vol. 39 No. 2 (2020): Bulletin of Pure and Applied Sciences Chemistry (Jul-Dec) 2020

Section

Articles

How to Cite

A review on Flurbiprofen: Therapeutic challenges in Emerging Active Metabolizing Biphenyl . (2020). Bulletin of Pure and Applied Sciences-Chemistry , 39(2), 77–89. https://doi.org/10.48165/